Ketorolac versus nepafenac in cataract surgery

References 

1. Duong H-VQ, Westfield KC, Chalkley THF. Ketorolac tromethamine LS 0.4% versus nepafenac 0.1% in patients having cataract surgery; prospective randomized double-masked clinical trial. J Cataract Refract Surg. 2007;33:1925–1929
   • Abstract
   • Full Text
   • Full-Text PDF (188 KB)
   • CrossRef
2. Tetz MR, Nimsgern C. Posterior capsule opacification. Part 2: clinical findings. J Cataract Refract Surg. 1999;25:1662–1674
   • Abstract
   • Full Text
   • Full-Text PDF (896 KB)
   • CrossRef
3. Inan ÜÜ, Bozkurt E, Öztürk F, et al. Effect of diclofenac on prevention of posterior capsule opacification in human eyes. Can J Ophthalmol. 2006;41:624–629Available at: http://pubs.nrc-cnrc.gc.ca/cjo/cjo41/i06-051.pdfAccessed December 4, 2007
4. İnan ÜÜ, Öztürk F, Kaynak S, et al. Prevention of posterior capsule opacification by intraoperative single-dose pharmacologic agents. J Cataract Refract Surg. 2001;27:1079–1087
   • Abstract
   • Full Text
   • Full-Text PDF (333 KB)
   • CrossRef